Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,560.40
(
1.93%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
-0.54%
)
Bitcoin
77,763.92
(
-0.66%
)
News Focus
News Focus
Post# of 447459
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

HDGabor

Send PM Follow Ignore
Followers 142
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

HDGabor

Re: dukesking post# 241122

Tuesday, 01/14/2020 8:17:34 PM

Tuesday, January 14, 2020 8:17:34 PM

Post# of 447459
d-

Hickma is projecting on assumptions that they will capture the Vascepa market which includes ReduceIt CVD label scripts to reach that value. There’s no way that they think the high triglyceride >500 would have those value estimations. They are implying that they expect a very large part of that estimate.

Hikma listed the targeted drugs …. and the revenue of these drugs (provided by IQVA).
They did not say anything about their expectation for market share* or revenue. (* no way that they will have 100% market share … $750 is the 100%)
The slide does not prove or hint anything other than they would like to sell generic version of these drugs (inc. Vascepa).

Best,
G

"There are some things money can't buy. … For these, there is AMRN."

Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News